Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group

S Groschel; RF Schlenk; J Engelmann; Veronika Rockova; V Teleanu; MWM Kuhn; K Eiwen; C Erpelinck; Marije Havermans; M Lubbert; U Germing; IGH Schmidt-Wolf; Berna Beverloo; GJ Schuurhuis; GJ Ossenkoppele; B Schlegelberger; LF Verdonck; E Vellenga; G Verhoef; P Vandenberghe; T Pabst; M Bargetzi; J Krauter; A Ganser; Peter Valk; Bob Löwenberg; K Dohner; H Dohner; Ruud Delwel

doi:10.1200/JCO.2011.41.5505

Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group

S Groschel, RF Schlenk, J Engelmann, Veronika Rockova, V Teleanu, MWM Kuhn, K Eiwen, C Erpelinck, Marije Havermans, M Lubbert, U Germing, IGH Schmidt-Wolf, Berna Beverloo, GJ Schuurhuis, GJ Ossenkoppele, B Schlegelberger, LF Verdonck, E Vellenga, G Verhoef, P VandenbergheT Pabst, M Bargetzi, J Krauter, A Ganser, Peter Valk, Bob Löwenberg, K Dohner, H Dohner, Ruud Delwel

Research output: Contribution to journal › Article › Academic › peer-review

84 Citations (Scopus)

Abstract

Purpose To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements. Patients and Methods We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group prospective treatment trials. Material was available from 177 AML patients for EVI1 expression analysis. Results We divided 286 MLL-rearranged AMLs into three subgroups: t(9;11)(p22;q23) (44.8%), t(6;11)(q27;q23) (14.7%), and t(v;11q23) (40.5%). EVI1 overexpression (EVI1(+)) was found in 45.8% of all patients with t(11q23), with t(6;11) showing the highest frequency (83.9%), followed by t(9;11) at 40.0%, and t(v;11q23) at 34.8%. Concurrent gene mutations were rare or absent in all three subgroups. Within all t(11q23) AMLs, EVI1(+) was the sole prognostic factor, predicting for inferior overall survival (OS Conclusion Deregulated EVI1 expression defines poor prognostic subsets among AML with t(11q23) and AML with t(9;11)(p22;q23). Patients with EVI1(+) MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR. J Clin Oncol 31:95-103. (c) 2012 by American Society of Clinical Oncology

Original language	Undefined/Unknown
Pages (from-to)	95-103
Number of pages	9
Journal	Journal of Clinical Oncology
Volume	31
Issue number	1
DOIs	https://doi.org/10.1200/JCO.2011.41.5505
Publication status	Published - 2013

Research programs

EMC MGC-02-96-01
EMC MM-02-41-03
EMC NIHES-01-66-01

Access to Document

10.1200/JCO.2011.41.5505

http://hdl.handle.net/1765/71288

Cite this

Groschel, S., Schlenk, RF., Engelmann, J., Rockova, V., Teleanu, V., Kuhn, MWM., Eiwen, K., Erpelinck, C., Havermans, M., Lubbert, M., Germing, U., Schmidt-Wolf, IGH., Beverloo, B., Schuurhuis, GJ., Ossenkoppele, GJ., Schlegelberger, B., Verdonck, LF., Vellenga, E., Verhoef, G., ... Delwel, R. (2013). Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. Journal of Clinical Oncology, 31(1), 95-103. https://doi.org/10.1200/JCO.2011.41.5505

@article{5309616fab364dc6baceb2fce5b3cc79,

title = "Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group",

abstract = "Purpose To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements. Patients and Methods We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group prospective treatment trials. Material was available from 177 AML patients for EVI1 expression analysis. Results We divided 286 MLL-rearranged AMLs into three subgroups: t(9;11)(p22;q23) (44.8%), t(6;11)(q27;q23) (14.7%), and t(v;11q23) (40.5%). EVI1 overexpression (EVI1(+)) was found in 45.8% of all patients with t(11q23), with t(6;11) showing the highest frequency (83.9%), followed by t(9;11) at 40.0%, and t(v;11q23) at 34.8%. Concurrent gene mutations were rare or absent in all three subgroups. Within all t(11q23) AMLs, EVI1(+) was the sole prognostic factor, predicting for inferior overall survival (OS Conclusion Deregulated EVI1 expression defines poor prognostic subsets among AML with t(11q23) and AML with t(9;11)(p22;q23). Patients with EVI1(+) MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR. J Clin Oncol 31:95-103. (c) 2012 by American Society of Clinical Oncology",

author = "S Groschel and RF Schlenk and J Engelmann and Veronika Rockova and V Teleanu and MWM Kuhn and K Eiwen and C Erpelinck and Marije Havermans and M Lubbert and U Germing and IGH Schmidt-Wolf and Berna Beverloo and GJ Schuurhuis and GJ Ossenkoppele and B Schlegelberger and LF Verdonck and E Vellenga and G Verhoef and P Vandenberghe and T Pabst and M Bargetzi and J Krauter and A Ganser and Peter Valk and Bob L{\"o}wenberg and K Dohner and H Dohner and Ruud Delwel",

year = "2013",

doi = "10.1200/JCO.2011.41.5505",

language = "Undefined/Unknown",

volume = "31",

pages = "95--103",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "1",

}

Groschel, S, Schlenk, RF, Engelmann, J, Rockova, V, Teleanu, V, Kuhn, MWM, Eiwen, K, Erpelinck, C, Havermans, M, Lubbert, M, Germing, U, Schmidt-Wolf, IGH, Beverloo, B, Schuurhuis, GJ, Ossenkoppele, GJ, Schlegelberger, B, Verdonck, LF, Vellenga, E, Verhoef, G, Vandenberghe, P, Pabst, T, Bargetzi, M, Krauter, J, Ganser, A, Valk, P , Löwenberg, B, Dohner, K, Dohner, H & Delwel, R 2013, 'Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group', Journal of Clinical Oncology, vol. 31, no. 1, pp. 95-103. https://doi.org/10.1200/JCO.2011.41.5505

Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. / Groschel, S; Schlenk, RF; Engelmann, J et al.
In: Journal of Clinical Oncology, Vol. 31, No. 1, 2013, p. 95-103.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group

AU - Groschel, S

AU - Schlenk, RF

AU - Engelmann, J

AU - Rockova, Veronika

AU - Teleanu, V

AU - Kuhn, MWM

AU - Eiwen, K

AU - Erpelinck, C

AU - Havermans, Marije

AU - Lubbert, M

AU - Germing, U

AU - Schmidt-Wolf, IGH

AU - Beverloo, Berna

AU - Schuurhuis, GJ

AU - Ossenkoppele, GJ

AU - Schlegelberger, B

AU - Verdonck, LF

AU - Vellenga, E

AU - Verhoef, G

AU - Vandenberghe, P

AU - Pabst, T

AU - Bargetzi, M

AU - Krauter, J

AU - Ganser, A

AU - Valk, Peter

AU - Löwenberg, Bob

AU - Dohner, K

AU - Dohner, H

AU - Delwel, Ruud

PY - 2013

Y1 - 2013

N2 - Purpose To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements. Patients and Methods We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group prospective treatment trials. Material was available from 177 AML patients for EVI1 expression analysis. Results We divided 286 MLL-rearranged AMLs into three subgroups: t(9;11)(p22;q23) (44.8%), t(6;11)(q27;q23) (14.7%), and t(v;11q23) (40.5%). EVI1 overexpression (EVI1(+)) was found in 45.8% of all patients with t(11q23), with t(6;11) showing the highest frequency (83.9%), followed by t(9;11) at 40.0%, and t(v;11q23) at 34.8%. Concurrent gene mutations were rare or absent in all three subgroups. Within all t(11q23) AMLs, EVI1(+) was the sole prognostic factor, predicting for inferior overall survival (OS Conclusion Deregulated EVI1 expression defines poor prognostic subsets among AML with t(11q23) and AML with t(9;11)(p22;q23). Patients with EVI1(+) MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR. J Clin Oncol 31:95-103. (c) 2012 by American Society of Clinical Oncology

AB - Purpose To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements. Patients and Methods We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group prospective treatment trials. Material was available from 177 AML patients for EVI1 expression analysis. Results We divided 286 MLL-rearranged AMLs into three subgroups: t(9;11)(p22;q23) (44.8%), t(6;11)(q27;q23) (14.7%), and t(v;11q23) (40.5%). EVI1 overexpression (EVI1(+)) was found in 45.8% of all patients with t(11q23), with t(6;11) showing the highest frequency (83.9%), followed by t(9;11) at 40.0%, and t(v;11q23) at 34.8%. Concurrent gene mutations were rare or absent in all three subgroups. Within all t(11q23) AMLs, EVI1(+) was the sole prognostic factor, predicting for inferior overall survival (OS Conclusion Deregulated EVI1 expression defines poor prognostic subsets among AML with t(11q23) and AML with t(9;11)(p22;q23). Patients with EVI1(+) MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR. J Clin Oncol 31:95-103. (c) 2012 by American Society of Clinical Oncology

U2 - 10.1200/JCO.2011.41.5505

DO - 10.1200/JCO.2011.41.5505

M3 - Article

C2 - 23008312

SN - 0732-183X

VL - 31

SP - 95

EP - 103

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 1

ER -

Groschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kuhn MWM et al. Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. Journal of Clinical Oncology. 2013;31(1):95-103. doi: 10.1200/JCO.2011.41.5505